Prosensa has received financing of $1.5m for three years from the charitable organization Charley’s Fund, to support development of compounds for the skipping of exon 52 in patients with Duchenne Muscular Dystrophy (DMD).
Under the terms of the agreement, Prosensa will identify antisense oligonucleotides for the skipping of exon 52 in specific subpopulations of DMD patients. Prosensa will assess the safety and efficacy of the compounds in suitable preclinical models with the aim to move a selected candidate into clinical trials.
“The company has already received financial support from Charley’s Fund and other groups during its early years. This additional support for the exon 52 program will enable us to accelerate our efforts towards clinical development,” says Luc Dochez, Prosensa’s chief business officer.
Release Date: Dec. 1, 2011